ANTONIO ALCI BARONE
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Seroprevalence of hepatitis E in adults in Brazil: a systematic review and meta-analysis(2019) TENGAN, Fatima Mitiko; FIGUEIREDO, Gerusa M.; NUNES, Arielle K. S.; MANCHIERO, Carol; DANTAS, Bianca P.; MAGRI, Mariana C.; PRATA, Thamiris V. G.; NASCIMENTO, Marisa; MAZZA, Celso C.; ABDALA, Edson; BARONE, Antonio A.; BERNARDO, Wanderley M.BackgroundHepatitis E virus (HEV) is a member of the Hepeviridae family; it has four main genotypes and one serotype. While genotypes 1 and 2 cause epidemic hepatitis and are transmitted via water and the fecal-oral route, genotypes 3 and 4 are zoonotic. In the various seroprevalence studies of hepatitis E in Brazil, the numbers reported vary widely and are difficult to interpret. The aim of this study was to analyze existing seroprevalence studies of hepatitis E in adults in Brazil.Main textWe searched the PubMed, Latin American and Caribbean Health Sciences and Embase databases for studies published from inception to May 12, 2018 concerning infection by HEV in Brazil without time period or language restrictions. We included studies that presented data concerning hepatitis E seroprevalence in adults in Brazil, had a sample size 50 patients and whose method used for the detection of anti-HEV was standardized and commercialized. We also evaluated the quality of the articles using a list of criteria that totalized 9 items. Of the 20 studies ultimately analyzed, 10 (50%) were from the southeast region of Brazil, 3 (15%) were from the central-west region, 3 (15%) were from the northern region, 2 (10%) were from the northeast region and 2 (10%) were from the southern region. Regarding the quality evaluation of the studies, the mean score was 5.6 (range: 4-8). The estimated overall seroprevalence of HEV infection in the adult population was 6.0% (95% CI: 5.0-7.0); in subgroup analyses, we observed that the prevalence of anti-HEV antibodies in blood donors was 7.0% (95% CI: 5.0-8.0), whereas in the general population, it was 3.0% (95% CI: 2.0-4.0).ConclusionsThe results of this systematic review indicate that there should be national investment in the prevention of hepatitis E virus infection in Brazil, including the implementation of improvements in basic sanitation and guidance regarding the appropriate handling of animal waste and the optimal cooking of vegetables, meat and their derivatives.
conferenceObject Lack of association between SOCS3 rs4969170 and interleukin 28B genes with therapeutic response in Brazilian HCV carriers treated with PEG-IFN/RBV(2012) MELO, Carlos E.; ARAUJO, Evaldo S.; MANCHIERO, Caroline; MARTINS, Luciane P.; TENGAN, Fatima M.; BARONE, Antonio A.Chronic HCV infections are related with the production of inappropriate cytokine levels in inflammatory and immune response. IFN-α must activate a signal transduction cascade that involves different intracellular proteins driving interferon-inducible genes to be activated. The proteins suppressor of cytokine signaling (SOCS) represents the main cellular mechanism for cytokine (such as IL10 and IFN) negative regulation. Immune responses may be associated with SOCS3 production driven by therapy against HCV and it seems to be regulated by single nucleotide polymorphisms (SNPs) within SOCS3 gene. Recently, genome-wide association studies have linked response to PEG-IFN/RBV therapy with SNPs near the IL28B gene (rs12979860), encoding for interferon-lambda-3 (IL28B). The rs12979860 CC genotype is associated with a greater rate of sustained virological response (SVR) than the CT or TT genotypes in different HCV patients populations. In this study, we evaluated the frequencies of SOCS3 and IL28B polymorphisms genes and their association with the response to IFN based antiviral therapy in chronic hepatitis C infection. After IRB ethics approval, frozen samples from 142 HCV Genotype-1 infected Brazilian patients were analyzed. Genomic DNA from patients classified as responders (R=71) and nonresponders (NR=71) to a PEG-IFN/RBV therapy were used in this study. The SNPs near the IL28B (rs12979860) and SOCS3 (rs4969170) genes were examined using an assay with allele specific PCR probes. According recent publications, IL28B CC genotype was considered the more favorable profile to reach Sustained Virologic Response (SVR). Regarding SOCS3 AA genotype was also recently strongly associated with failure of the IFN-α based therapy. The results are summarized in the table 1. As expected IL28B CC SNP was associated with a better response to antiviral therapy. Conversely, we could not observe a clear association between the polymorphism rs4969170 SOCS3 gene and lack of response to IFN based therapy in our population. Therefore we conclude that the SOCS3 rs4969170 was not as good as IL28B on predicting therapy outcome for HCV.- Prevalence of multidrug-resistant tuberculosis in Latin America and the Caribbean: a systematic review and meta-analysis(2020) TENGAN, Fatima M.; FIGUEIREDO, Gerusa M.; LEITE, Olavo H. M.; NUNES, Arielle K. S.; MANCHIERO, Carol; DANTAS, Bianca P.; MAGRI, Mariana C.; BARONE, Antonio A.; BERNARDO, Wanderley M.Objectives To evaluate the prevalence of multidrug-resistant tuberculosis (MDR-TB) in individuals living in Latin America and the Caribbean (LAC). Methods We searched the MEDLINE, Embase and Literatura Latino Americana e do Caribe em Ciencias da Saude (Lilacs) databases until 08 August 2019 for all studies on the subject, without time or language restrictions. Original studies reporting the prevalence of infection withMycobacterium tuberculosisresistant to isoniazid and rifampicin simultaneously (MDR) in LAC, the prevalence of resistance in cases with no previous treatment (new cases) and the prevalence of resistance in previously treated cases were selected. Considering the expected heterogeneity between studies, all analyses were performed using the random effects model, and heterogeneity was assessed using the I(2)statistic. Results We included 91 studies from 16 countries. The estimated overall prevalence was 13.0% (95% CI 12.0-14.0%), and the heterogeneity between studies was substantial (I-2 = 96.1%). In the subgroup analyses, it was observed that the prevalence of MDR-TB among new cases was 7.0% (95% CI 6.0-7.0%) and in previously treated cases was 26.0% (95% CI 24.0-28.0%). Conclusions This review highlights multidrug resistance to antituberculosis drugs in LAC, indicating that prevention strategies have not been effective. Government institutions should invest heavily in strategies for early diagnosis and the rapid availability of effective treatments and prioritise adequate protection for health professionals. In addition, screening programmes should be adopted to prevent secondary cases.